Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of “Moderate Buy” from Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $19.00.

A number of equities research analysts have issued reports on the stock. Raymond James Financial initiated coverage on shares of Lexeo Therapeutics in a report on Wednesday, December 17th. They set a “strong-buy” rating and a $25.00 price objective for the company. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Chardan Capital reiterated a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, January 13th. Cantor Fitzgerald started coverage on shares of Lexeo Therapeutics in a report on Monday, December 1st. They set an “overweight” rating and a $19.00 price objective for the company. Finally, Leerink Partners raised their price objective on Lexeo Therapeutics from $9.00 to $20.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. CWM LLC lifted its position in Lexeo Therapeutics by 150.3% during the second quarter. CWM LLC now owns 10,351 shares of the company’s stock valued at $42,000 after purchasing an additional 6,216 shares during the last quarter. Ethic Inc. purchased a new stake in shares of Lexeo Therapeutics during the 2nd quarter valued at about $44,000. Cerity Partners LLC purchased a new stake in shares of Lexeo Therapeutics during the 2nd quarter valued at about $50,000. Intech Investment Management LLC lifted its holdings in shares of Lexeo Therapeutics by 20.7% in the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock valued at $55,000 after acquiring an additional 2,342 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Lexeo Therapeutics in the second quarter worth about $60,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Stock Down 0.4%

NASDAQ:LXEO opened at $7.23 on Thursday. The business’s 50-day simple moving average is $9.31 and its two-hundred day simple moving average is $7.24. Lexeo Therapeutics has a 52 week low of $1.45 and a 52 week high of $10.99. The stock has a market cap of $527.72 million, a PE ratio of -2.68 and a beta of 1.75.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Wednesday, November 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.15. Sell-side analysts anticipate that Lexeo Therapeutics will post -3.14 earnings per share for the current fiscal year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.